Sermorelin vs ipamorelin: how the two peptides compare

Last updated 2026-07-24

What is the basic difference between sermorelin and ipamorelin?

Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH), covering the first 29 amino acids of the natural 44-amino-acid hormone, which is the portion needed for full biological activity ^[1]. It binds the GHRH receptor on the pituitary and tells it to release growth hormone, using the same signaling pathway your body uses on its own. Ipamorelin is a different class of molecule entirely. It's a five-amino-acid peptide that mimics ghrelin, the "hunger hormone," and binds the growth hormone secretagogue receptor (GHS-R) instead of the GHRH receptor ^[2]. It triggers GH release through a separate pathway. In lab and clinical studies it does so with little to no effect on cortisol, prolactin, or appetite hormones compared to older secretagogues like GHRP-6 ^[2]. The practical result: sermorelin works upstream, amplifying your body's own GHRH signal. Ipamorelin works on a parallel switch. Combined use (a GHRH analog plus a ghrelin mimetic) is common in compounding practice because the two pathways are additive, but that combination itself has not been through FDA review as a fixed product. Neither peptide is anabolic steroid-like. Both depend on a working pituitary gland; if the gland can't respond, neither drug will produce meaningful GH.

How does the regulatory history compare: was either one FDA-approved?

Sermorelin has a real FDA history that most peptides sold now do not. It was approved and marketed in the US under the brand name Geref for diagnostic and pediatric growth hormone deficiency indications. The manufacturer discontinued Geref for business reasons, not because of a safety recall or a failed post-market study; FDA's own Drugs@FDA database lists it among discontinued products, a category distinct from a safety-driven withdrawal ^[3]. That history matters for anyone comparing sourcing decisions between the two. Sermorelin's approval history means there's a real prescribing label, a documented dose-response record, and known pharmacokinetics on file at FDA at some point. Ipamorelin has never had FDA approval for any human indication. It exists almost entirely as a research compound and, more recently, as a compounded pharmacy product, meaning its dosing conventions come from clinical practice and small trials rather than an approved label. Compounded versions of both peptides are legal only when compounded for an individual patient under a valid prescription, following the framework Congress set out for compounded drugs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013 ^[4]. Neither peptide currently has a finalized place on FDA's list of bulk drug substances that compounders may use without further restriction, so sourcing quality and legal status vary by state board and by pharmacy. That's worth reading about before ordering from any provider, and our sermorelin reviews piece walks through what a legitimate script-based purchase looks like.

How do their effects on growth hormone actually compare?

Both raise GH in pulses rather than producing the flat, sustained elevation you get from injecting recombinant HGH directly. Sermorelin's GHRH-driven pulse mimics the body's natural nighttime GH surge fairly closely, because it uses the same receptor and largely the same downstream cascade as endogenous GHRH ^[1]. Ipamorelin studies, mostly small and some going back over two decades, show it produces a GH pulse of a magnitude comparable to, or in some protocols larger than, a single GHRH-class dose, without significantly raising cortisol or prolactin, a problem that plagued earlier ghrelin mimetics like GHRP-6 ^[2]. The foundational pharmacology paper by Raun and colleagues, published in the European Journal of Endocrinology in 1998, established ipamorelin's selectivity for GH release over other pituitary hormones in animal and early human work ^[2]. Neither peptide has been shown in controlled human trials to produce IGF-1 elevations, body composition changes, or clinical outcomes on par with direct recombinant HGH therapy. Most of the modern comparative data is pharmacology-level (GH pulse amplitude, receptor binding, hormone specificity), not long-term outcome data like lean mass or fat loss in healthy adults. If you're the kind of reader who wants outcome studies, more than pulse-amplitude studies, you won't find much for either compound. That gap is real and worth acknowledging up front rather than glossing over.

Sermorelin vs ipamorelin: side-by-side comparison

How does dosing differ between sermorelin and ipamorelin?

Sermorelin is typically dosed in the 200 to 300 mcg range, given as a single subcutaneous injection before bed, timed to the body's natural overnight GH pulse ^[1]. Original Geref labeling for pediatric diagnostic use specified weight-based dosing (around 1 mcg/kg) for the GH stimulation test, which is different from the flat-dose regimens used in current off-label adult protocols. The diagnostic use and the off-label longevity-clinic use are not the same clinical context, and dosing conventions for the latter come from prescriber experience, not an approved label. Ipamorelin dosing in compounded practice commonly runs 200 to 300 mcg per injection, once or twice daily, sometimes combined with a GHRH analog like sermorelin or CJC-1295. Because there is no FDA-approved label, these numbers come from clinical compounding conventions and small studies, not a fixed dose-response chart validated in large trials. If your prescriber is proposing a specific regimen, ask what it's based on: an approved label, a peer-reviewed trial, or clinic experience. All three are legitimate reasons to try something, but they carry very different levels of certainty, and you deserve to know which one you're getting. For actual numbers and how they scale by body weight and goal, see the sermorelin dosage chart and the sermorelin dosage calculator.

Which one has better safety data: sermorelin or ipamorelin?

Sermorelin's safety profile is better documented, largely because it went through FDA review at some point in its history. Common reported effects include injection site redness, flushing, headache, and dizziness, consistent with older Geref labeling and modern compounded-use reports ^{[1] [3]}. Ipamorelin's safety data is thinner. Its selectivity for GH release over cortisol and prolactin is one of its selling points in the peptide literature ^[2], but most of that literature is short-term pharmacology work, not multi-year safety follow-up in adults using it for body composition or wellness goals. Nobody has good long-term data on either peptide used for months or years in healthy, non-GHD adults; that's true across the class, more than for ipamorelin specifically. Because both peptides work by increasing GH and downstream IGF-1, theoretical long-term concerns (effects on insulin sensitivity, possible growth of hormone-sensitive tissue) apply to both, even though clinical case reports remain rare. If you want the fuller list of documented and theoretical risks, read sermorelin long-term side effects before starting either peptide, since much of the reasoning applies across GHRH analogs and secretagogues alike.

Sermorelin vs HGH: is sermorelin actually a substitute for growth hormone therapy?

This is the question most readers actually came here to answer, and the honest response is: sometimes, but not as a strict substitute. Recombinant human growth hormone (somatropin) is the GH molecule itself, delivered directly, bypassing the pituitary entirely. Sermorelin is a signal that asks the pituitary to make its own GH. If someone's pituitary is severely damaged or absent (from surgery, radiation, or congenital conditions), sermorelin won't work well because there's no gland left to respond. FDA-approved recombinant HGH products are indicated for specific diagnosed conditions: pediatric growth hormone deficiency, Turner syndrome, chronic kidney disease-related growth failure, and adult GH deficiency confirmed by stimulation testing, among others, and each product carries its own FDA label with specific indications ^[5]. Sermorelin, in its approved history, was positioned mainly as a diagnostic agent and pediatric GHD treatment, not as a general adult GH-deficiency substitute, and its current off-label adult use is exactly that: off-label. Where sermorelin genuinely loses to HGH: magnitude and reliability of effect. Direct HGH injection produces a much larger, more predictable rise in IGF-1 and GH-dependent effects because it isn't dependent on pituitary responsiveness or receptor downregulation. For diagnosed adult GH deficiency where a real clinical effect size matters, recombinant HGH has the stronger evidence base and the approved label to back it. Where sermorelin has a legitimate edge: it preserves the body's own pulsatile GH release pattern rather than overriding it, and it carries a lower risk of shutting down natural pituitary function the way exogenous HGH can, because it stimulates rather than replaces. It's also cheaper and, for people who are not GH-deficient but are curious about mild stimulation of their own GH axis under medical supervision, it's a lower-intensity starting point. But don't mistake "lower intensity" for "clinically proven equivalent." It isn't. For the full head-to-head with numbers on cost and effect size, read sermorelin, which lays out the evidence base in more depth.

Where does ipamorelin fit compared to HGH?

Ipamorelin sits in roughly the same tier as sermorelin relative to HGH: it's a stimulator, not a replacement, and it depends on a functioning pituitary. Its main claimed advantage over sermorelin, and by extension over generic secretagogue therapy, is hormone specificity: less cortisol and prolactin spillover in early studies ^[2]. But "less side-hormone spillover" is not the same claim as "comparable efficacy to HGH." No trial has shown ipamorelin monotherapy matches recombinant HGH for IGF-1 elevation or clinical outcomes in adults. Most protocols that aim for a stronger effect combine ipamorelin with a GHRH analog (sermorelin or CJC-1295), on the theory that stacking two different receptor pathways produces a bigger combined pulse than either alone. That combination theory is plausible pharmacologically, but combination-specific human outcome trials are limited.

Which one costs more, sermorelin or ipamorelin?

Compounded pricing varies a lot by pharmacy, region, and dose, and neither has a fixed retail price the way an FDA-approved drug with an NDC and standard insurance billing code would. As a general pattern reported across compounding pharmacies and telehealth peptide clinics, sermorelin and ipamorelin monotherapy tend to land in similar monthly ranges, often cited informally in the low hundreds of dollars per month for typical adult protocols, though exact figures depend entirely on the dispensing pharmacy and are not standardized or FDA-published. Combination products (sermorelin plus ipamorelin, or GHRH analog plus ghrelin mimetic) usually cost more than either alone, since you're paying for two active peptides in one vial. Because neither is FDA-approved for this use, none of this is covered by insurance, and none of it has a published federal reference price the way a generic drug would through a state Medicaid formulary, for example. Get an actual quote from a licensed pharmacy before assuming any number you read online, including any range mentioned here, applies to your prescription.

Can you combine sermorelin and ipamorelin, and is that better than either alone?

Yes, combining them is common in compounded practice, and the pharmacological logic is sound: sermorelin stimulates the GHRH receptor pathway while ipamorelin stimulates the separate ghrelin receptor pathway, so in theory the two effects stack rather than compete ^{[1] [2]}. Some compounded products are sold as a fixed-ratio blend for this reason. What's missing is a large, controlled human trial measuring whether the combination produces meaningfully better clinical outcomes (more than bigger GH pulses on a lab measurement) than either peptide alone. If your prescriber recommends a combination, it's reasonable to ask what specific outcome they expect to improve and over what timeframe, and to understand that the recommendation rests on receptor pharmacology and clinical experience, not a completed head-to-head outcomes trial.

How should you actually choose between them?

Start with why you're considering either one. If you have diagnosed adult growth hormone deficiency confirmed by a stimulation test, that's a conversation for an endocrinologist about FDA-approved recombinant HGH first, since it has the deeper evidence base and an approved label for that exact indication ^[5]. Sermorelin and ipamorelin are not first-line replacements for a documented GHD diagnosis. If you're a generally healthy adult curious about mild GH-axis stimulation under medical supervision, sermorelin's regulatory history (a real former FDA approval, discontinued for business reasons, with known pharmacokinetics) gives it a slightly more documented track record than ipamorelin, which has never carried an FDA approval for any indication. That's not a guarantee sermorelin is more effective; it's a statement about how much is actually on the public record. Either way, the choice should run through a licensed prescriber who reviews your labs (IGF-1, morning cortisol, thyroid panel at minimum) before writing anything, and through a pharmacy that compounds under a real prescription rather than shipping product with no medical oversight. Sermorelin Co's provider-reviewed route connects you to that kind of prescriber conversation and names its fulfilling pharmacy partner up front, rather than leaving you to guess at sourcing quality on your own. Whatever peptide you land on, ask to see the pharmacy's licensing and compounding registration before you pay for anything, and read up on where to source responsibly at sermorelin peptide near me.

Frequently asked questions

Is ipamorelin stronger than sermorelin?

Not clearly. Ipamorelin produces a GH pulse of comparable or sometimes larger magnitude in small pharmacology studies, with less cortisol and prolactin spillover than older secretagogues ^[2]. Sermorelin mimics the body's natural GHRH pulse more directly ^[1]. Neither has been shown in controlled trials to outperform the other on clinical outcomes like body composition or IGF-1 elevation over time.

Which is safer, sermorelin or ipamorelin?

Sermorelin has more documented safety history because it held FDA approval as Geref before being discontinued for business reasons ^[3]. Ipamorelin has never been FDA-approved, so its safety data comes mainly from small studies and compounded-use reports. Both share theoretical long-term risks tied to raising GH and IGF-1, and neither has solid multi-year safety data in healthy adults.

Was sermorelin taken off the market for safety reasons?

No. The branded product Geref was discontinued by its manufacturer, and FDA's Drugs@FDA records reflect this as a market discontinuation rather than a safety-driven withdrawal or recall ^[3]. Sermorelin itself remains available today through compounding pharmacies under a valid prescription, following FDA's compounding framework ^[4].

Can sermorelin and ipamorelin be used together?

Yes, combining a GHRH analog like sermorelin with a ghrelin mimetic like ipamorelin is common in compounded protocols, since the two work on separate receptor pathways and may produce an additive GH pulse ^[1][2]. Large controlled trials confirming better clinical outcomes from the combination, versus either drug alone, are still lacking.

Does sermorelin or ipamorelin work better for weight loss?

Neither has strong clinical trial evidence supporting weight loss as a primary outcome in healthy adults. Both raise GH pulses, and GH influences fat metabolism in a general sense, but neither peptide is FDA-approved or well-studied for weight loss specifically. Treat any weight-loss claim from a clinic as marketing until backed by a cited trial.

Is ipamorelin FDA-approved?

No. Ipamorelin has never received FDA approval for any human indication. It's available only through compounding pharmacies under a prescription, following the FD&C Act's 503A/503B compounding framework ^[4], which is a different and less rigorous regulatory pathway than full drug approval.

How is sermorelin dosed compared to ipamorelin?

Sermorelin is typically dosed around 200 to 300 mcg subcutaneously once nightly, timed to natural sleep-related GH release ^[1]. Ipamorelin is commonly dosed in a similar 200 to 300 mcg range, sometimes twice daily given its roughly 2-hour half-life versus sermorelin's 10 to 20 minute half-life. Neither has an FDA-approved dosing label for adult off-label use.

Does either sermorelin or ipamorelin raise cortisol or prolactin?

Ipamorelin was specifically developed to avoid the cortisol and prolactin elevation seen with older ghrelin-mimetic peptides like GHRP-6, and early studies confirm relative selectivity for GH release ^[2]. Sermorelin, working through the natural GHRH pathway, also shows minimal cortisol or prolactin effect in its historical labeling data ^[1][3].

Is sermorelin the same as HGH?

No. Sermorelin is a GHRH analog that signals your pituitary to make its own growth hormone. HGH (somatropin) is the growth hormone molecule itself, given directly. Sermorelin depends on a working pituitary gland; direct HGH does not. HGH has a larger, more predictable effect and a broader set of FDA-approved indications ^[5].

Why would someone choose sermorelin over HGH?

Sermorelin preserves the body's natural pulsatile GH release pattern rather than overriding it, generally costs less than recombinant HGH, and carries a real (if now discontinued) FDA approval history as Geref ^[3]. It's a lower-intensity option for people without a confirmed GH-deficiency diagnosis, not a proven equivalent substitute for approved HGH therapy.

How much does sermorelin or ipamorelin cost per month?

Compounded pricing varies widely by pharmacy and dose, with no fixed federal reference price since neither is FDA-approved for adult off-label use. Reported monthly costs across telehealth clinics commonly fall in the low hundreds of dollars, but get a direct quote from a licensed pharmacy rather than relying on any online estimate, including this one.

Can I take ipamorelin without a prescription?

You can legally obtain compounded ipamorelin only under a valid prescription from a licensed prescriber, compounded by a pharmacy operating under FD&C Act sections 503A or 503B ^[4]. Products sold as "research chemicals" without a prescription fall outside that legal framework and carry unknown purity, dosing accuracy, and sourcing risk.

Sources

1. StatPearls (NCBI Bookshelf), "Sermorelin", updated 2023: Sermorelin is a 29-amino-acid GHRH analog that stimulates the pituitary GHRH receptor to release growth hormone
2. Raun K, et al., "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, 1998, PMID 9713333: Ipamorelin is a ghrelin-mimetic pentapeptide selective for GH release with minimal cortisol/prolactin effect compared to GHRP-6
3. U.S. Food and Drug Administration, Drugs@FDA database, Geref (sermorelin acetate) NDA 019667: Geref (sermorelin) was discontinued by its manufacturer and is listed as a market discontinuation, not a safety withdrawal
4. Drug Quality and Security Act, Public Law 113-54 (2013), amending FD&C Act sections 503A and 503B: Compounded peptides like sermorelin and ipamorelin are legally produced under FD&C Act sections 503A and 503B for individual patient prescriptions
5. U.S. Food and Drug Administration, Drugs@FDA database, Genotropin (somatropin) NDA 020280: Recombinant HGH products carry FDA-approved labels for specific indications including pediatric GHD, Turner syndrome, and adult GH deficiency
6. MedlinePlus (National Library of Medicine), Growth Hormone Deficiency: Growth hormone deficiency in adults and children is diagnosed through stimulation testing and confirmed low IGF-1 levels
7. National Center for Biotechnology Information, PubChem Compound Summary for Ipamorelin, CID 9831659: Ipamorelin is a five-amino-acid synthetic peptide that acts as a growth hormone secretagogue receptor agonist